|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrate the potential clinical utility of PLGA nanotechnology-based cancer vaccine to enhance BCMA-targeted immunotherapy against myeloma.
|
31427721 |
2020 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor (CAR) T-cell therapy targeting BCMA produced unprecedented results in heavily pretreated relapsed and/or refractory MM.
|
31780814 |
2020 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a proof-of-concept study to demonstrate that ultra-small (<5 nm) gadolinium-containing nanoparticles bound to full-length antibodies against the B-cell maturation antigen (BCMA) exhibit rapid tumor uptake followed by renal clearance, improving the signal-to-noise ratio for MM detection beyond levels that are currently afforded by other FDA-approved clinical imaging modalities.
|
31650133 |
2019 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For multiple myeloma (MM), B-cell maturation antigen (BCMA) has been recently proved to be a promising target.
|
31847470 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these results demonstrate that circulating BCMA levels in most RRMM patients are high enough to interfere with anti-BCMA antibody binding to MM tumor cells and may interfere with BCMA-targeted immune-based therapies.
|
31035033 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
|
31434693 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma.
|
31042825 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor (CAR) engineered T cells targeting B cell maturation antigen (BCMA), CD138, CS1 glycoprotein antigen (SLAMF7) and light chains are in active development for therapy of refractory /relapsed (RR) MM.
|
31684964 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum BCMA is elevated in patients with multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), and might represent a novel prognostic and monitoring tool.
|
30810049 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study is to target the BCMA, which promotes MM cell growth and survival, by generating BCMA-specific memory CD8<sup>+</sup> CTL that mediate effective and long-lasting immunity against MM.
|
30872779 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The encouraging results of chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen (BCMA) immunotherapy clinical trials have shed light on curing MM in recent years.
|
30693373 |
2019 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we conducted the clinical trial of a biepitope-targeting CAR T against B cell maturation antigen (BCMA) (LCAR-B38M) in 17 R/R MM cases.CAR T cells were i.v. infused after lymphodepleting chemotherapy.
|
30988175 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a phase I study of autologous T cells lentivirally-transduced with a fully-human, BCMA-specific CAR containing CD3ζ and 4-1BB signaling domains (CART-BCMA), in subjects with relapsed/refractory MM.
|
30896447 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
|
31005597 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additional ADCs and bispecific antibodies targeting BCMA and other surface antigens (eg, CD38, CD46, CD48, FcRH5, and G protein-coupled receptor, class C group 5 member D) are moving forward in phase 1 trials and may provide even more options for MM patients.
|
31808859 |
2019 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that exposure of myeloma cell lines and patient tumor samples to GSIs markedly increased surface BCMA levels in a dose-dependent fashion, concurrently decreased sBCMA concentrations, and improved tumor recognition by CAR T cells in vitro.
|
31558469 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, GPRC5D(109) CAR T cell therapy shows potential for the treatment of advanced MM irrespective of previous BCMA-targeted therapy.
|
30918115 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
|
31277554 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
B-cell maturation antigen (BCMA) represents an ideal therapeutic target in myeloma because of its high expression rate and high specificity for myeloma cells.
|
31094254 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
B-cell maturation antigen (BCMA) is expressed by normal and malignant plasma cells and is targeted via anti-BCMA chimeric antigen receptor T-cell therapy (BCMA CAR T-cell therapy) in plasma cell myeloma (PCM) patients.
|
30053652 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data corroborate BCMA is a suitable target in B cell tumors beyond MM, providing a novel therapeutic option for patients where BCMA is expressed at low abundance or where anti-CD19 immunotherapies have failed due to antigen loss.
|
30078440 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
B cell maturation antigen (BCMA) has recently been identified as an important multiple myeloma (MM)-specific target for chimeric antigen receptor (CAR) T cell therapy.
|
29678657 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blood CAR-BCMA T cells were predominantly highly differentiated CD8<sup>+</sup> T cells 6 to 9 days after infusion.BCMA antigen loss from MM was observed.
|
29812997 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCMA is also solubilized in the blood (soluble BCMA [sBCMA]) and MM patients with progressive disease have significantly higher sBCMA levels than those responding to treatment. sBCMA circulating in the blood may limit the efficacy of these anti-BCMA-directed therapies.
|
29230672 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
B cell maturation antigen (BCMA), a plasma cell surface antigen and member of the tumor necrosis factor (TNF) receptor superfamily, is an attractive target for immunotherapy of multiple myeloma due to its high prevalence on malignant plasma cells.
|
29899820 |
2018 |